Carson Wealth (CWM LLC)
ACRV icon

Carson Wealth (CWM LLC)’s Acrivon Therapeutics ACRV Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-127
Closed – – 5344
2025
Q3 		$0 Sell
127
-663
-84% -$932 ﹤0.01% 5232
2025
Q2 		$1K Buy
790
+741
+1,512% +$1.02K ﹤0.01% 4958
2025
Q1 		$0 Buy
49
+8
+20% +$43 ﹤0.01% 5033
2024
Q4 		$0 Sell
41
-5
-11% -$36 ﹤0.01% 4877
2024
Q3 		$0 Buy
46
+23
+100% +$181 ﹤0.01% 4787
2024
Q2 		$0 Buy
23
+20
+667% +$161 ﹤0.01% 4552
2024
Q1 		$0 Buy
+3
New +$14 ﹤0.01% 4279

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Carson Wealth (CWM LLC)'s ACRV Position: Q4 2025 in Review

Carson Wealth (CWM LLC) sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 127 shares.

Carson Wealth (CWM LLC) first reported a position in ACRV in Q1 2024 and held it in 7 quarters. The position peaked at $1K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

  • Carson Wealth (CWM LLC) reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 127 Acrivon Therapeutics shares in Q4 2025.
  • Carson Wealth (CWM LLC) first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 7 quarters.
  • Carson Wealth (CWM LLC)'s Acrivon Therapeutics position peaked at $1K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q4 2025, filed 26 Jan 2026.